Results 71 to 80 of about 7,154 (184)

Real-world effectiveness of nirmatrelvir-ritonavir versus azvudine in hospitalized patients with COVID-19 during the omicron wave in Beijing: a multicenter retrospective cohort study

BMC Infectious Diseases
Background and aim Two oral antivirals (Nirmatrelvir- ritonavir and Azvudine) are widely used in China practice during the Omicron wave of the pandemic.
Xiaobo Han, Darui Gao, Chenglong Li, Xin Yuan, Junchang Cui, Weiguo Zhao, Fei Xie, Kaifei Wang, Yuhong Liu, Guoxin Muo, Na Xi, Mengli Zheng, Rentao Wang, Kun Xiao, Dahui Zhao, Xinxin Zhang, Xinjie Han, Bo Wang, Tiantian Zhang, Wuxiang Xie, Lixin Xie   +20 more
doaj   +1 more source

Emerging small-molecule antiviral agents in long COVID prevention

Frontiers in Pharmacology
Long COVID, or Post-Acute Sequelae of COVID-19 (PASC), was characterized by persistent symptoms such as fatigue, shortness of breath, and cognitive impairments.
Xiaomeng He, Xiang Zhang, Wu Zhong
doaj   +1 more source

Fragment‐Based Design of Targeted Covalent Inhibitors: The Scope and Limitation of Linking Approaches

ChemMedChem, Volume 21, Issue 10, 27 May 2026.
This paper by Kollár et al. reports a covalent fragment linking study against the SARS‐CoV‐2 main protease (3CLPro). Beginning with inactive fragment hits, the application of rational linker design enabled the generation of reversible covalent inhibitors exhibiting low micromolar potency. The study details some general limitations and best practices of
Levente Kollár, Levente M. Mihalovits, Dávid Bajusz, Damijan Knez, József Simon, Blake H. Balcomb, Daren Fearon, Stanislav Gobec, György M. Keserű   +8 more
wiley   +1 more source

Inhibitors Targeting SARS‐CoV‐2 Papain‐Like Protease: Screening, Design, Synthesis, and Biological Evaluation

ChemMedChem, Volume 21, Issue 9, 14 May 2026.
In our study, we obtained both non‐covalent and covalent PLpro inhibitors. Additionally, the stable protein‐ligand interactions of the active compound were examined using advanced computational docking and molecular dynamics simulations. The non‐covalent inhibitor 2t showed antiviral activity with an EC50 of 2.89 µM, indicating its potential as a ...
Elena‐Oriana Iuga, Nilu Gone, Mariana Ortiz de Godoy, Gabriel Correa Verissimo, Giovanna de Jesus Agostinetto, Liam Urich, Nadine Krüger, Thales Kronenberger, Rafael Victorio Carvalho Guido, Anthony J. O’Donoghue, Stefan A. Laufer, Thanigaimalai Pillaiyar   +11 more
wiley   +1 more source

Severe Occupational Hypersensitivity Pneumonitis: A Case Series of Four Patients Requiring Lung Transplantation

American Journal of Industrial Medicine, Volume 69, Issue 5, Page 323-334, May 2026.
ABSTRACT Hypersensitivity pneumonitis (HP) is an immune‐mediated interstitial lung disease triggered by repeated inhalation of organic or chemical antigens. Occupational exposures account for approximately 19% of all cases. Early diagnosis, identification of the responsible antigen(s), and immediate avoidance of exposure are crucial to prevent ...
Ludwig Frei‐Stuber, Judith Mohren, Ester Mau, Bernhard Werner, Rudolf A. Hatz, Jürgen Barton, Dennis Nowak   +6 more
wiley   +1 more source

Impact of Early COVID‐19 Antiviral Therapy on the Incidence of Uveitis: A Retrospective Cohort Study Using the TriNetX Database

Immunity, Inflammation and Disease, Volume 14, Issue 5, May 2026.
ABSTRACT Objective To assess whether antivirals are associated with a reduced incidence of uveitis following COVID‐19. Methods We conducted a multi‐institutional, population‐based retrospective cohort study of adults (≥ 18 years) diagnosed with COVID‐19 between 2022 and 2024. Patients who received antiviral agents (Paxlovid, Molnupiravir, or Remdesivir)
Hou‐Ting Kuo, Alan Y. Hsu, De‐Yi Liu, Bing‐Qi Wu, James Cheng‐Chung Wei, Ning‐Yi Hsia, Yi‐Ching Shao, Chun‐Ting Lai, Chun‐Chi Chiang, Chun‐Ju Lin, Huan‐Sheng Chen, Yu‐Hsun Wang, Hsin Tseng, Ho‐Che Hsu, Yi‐Yu Tsai   +14 more
wiley   +1 more source

Carbohydrate‐Based Drug Discovery: Synthetic Strategies and Clinical Applications

Israel Journal of Chemistry, Volume 66, Issue 3, May 2026.
The picture depicts the molecules discussed in the review. On the left side, the general scaffold of sugars is shown. Next to it are four carbohydrate‐based molecules, including remdesivir, islatravir, empagliflozin, and Globo‐H. Remdesivir and islatravir contain a substituted ribose ring attached to a modified nucleobase.
Stephan Scheeff, Jemma Arakelyan, Billy Wai‐Lung Ng   +2 more
wiley   +1 more source

Extending the Targets for Coronavirus Antivirals Beyond That of Approved Drugs: Insights From Preclinical Research

Microbial Biotechnology, Volume 19, Issue 5, May 2026.
Chemical structure of RIBOTAC inhibitor with metabolic handle binding as nucleotide analogue to SARS‐CoV‐2 RNA dependent RNA polymerase, its linker and the RNase L recruiter which binds RNase L monomers and mediates their dimerization that actives nuclease activity degrading the viral RNA.
Harald Brüssow
wiley   +1 more source

A Sustainable Synthesis of the SARS-CoV-2 Mpro Inhibitor Nirmatrelvir, the Active Ingredient in Paxlovid

, 2022
A 7-step, 3-pot synthesis of the antiviral drug nirmatrelvir is described, arriving at the targeted drug in 70% overall yield. Critical amide bond-forming steps utilize new green technology that completely avoids traditional peptide coupling reagents, as
Donald H., Aue, Bruce H., Lipshutz, Juan C., Caravez, Joseph R. A., Kincaid, Karthik S., Iyer, Rahul D., Kavthe, Nico, Fleck   +6 more
core   +1 more source

Potential drug-drug interactions (DDI) with nirmatrelvir/ritonavir.

, 2023
Potential drug-drug interactions (DDI) with nirmatrelvir/ritonavir.
Grace Ho (4057195), Andrea Llanes (17241774), Amanda Stagg (17241780), Valerie Leung (7435043), Christopher Kandel (69857), Suzanne Gill (3427097), Jeff Powis (587575), Armughan Khawaja (17241777), Janine McCready (3427100), Mariana Jacubovich (17241783)   +9 more
core   +1 more source